Polidocanol foam sclerotherapy

Phase 3Small molecule

Polidocanol foam sclerotherapy is one of 3 small molecule programs targeting Varicose veins. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Varicose VeinsActive, not recruiting

TelangiectasiasActive, not recruiting

Varicose VeinsPreclinical

Active, not recruiting

TelangiectasiasPhase 3

Active, not recruiting

Competition

Competitive Landscape

2 competitors in Varicose Veins

#DrugCompanyPhaseTrials

Heparin Sodium

BBaxter Healthcare Corporation

Approved

—2

Polidocanol foam sclerotherapy

HHospital Universitario Pedro Ernesto

Phase 3

1 3

Calcium Dobesilate

GGuizhou Bailing Group Pharmaceutical Co Ltd

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

ApprovedActive, not recruiting

Telangiectasias

NCT07793630

Q4 2027

N/ANot yet recruiting

Varicose Veins

NCT07276243

Clinical

Trials by Indication[1]

Hemorrhoid1 trial

Polidocanol Foam VS Artery Ligation in Hemorrhoidal Disease

Completed·UUniversidade do Porto·Phase 2/3·NCT04675177·45 enrolled

Varicose veins1 trial

Polidocanol Foam With or Without Transdermal Laser for Varicose Veins: Randomized Clinical Trial

Not yet recruiting·HHospital Universitario Pedro Ernesto·N/A·NCT07276243·102 enrolled

Telangiectasias1 trial

Comparison Between Isolated Foam Sclerotherapy and Foam Sclerotherapy Combined With Transdermal Laser for the Treatment of Reticular Veins and Telangiectasias: A Prospective Randomized Clinical Trial

Active, not recruiting·UUniversity of Sao Paulo·Approved·NCT07793630·70 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Polidocanol foam sclerotherapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Polidocanol foam sclerotherapy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Polidocanol foam sclerotherapy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Hospital Universitario Pedro Ernesto company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: HHospital Universitario Pedro Ernesto

Polidocanol foam sclerotherapy

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q4 2027

Trials by Indication[1]

Hemorrhoid1 trial

Varicose veins1 trial

Telangiectasias1 trial

References

Drug Info

Quick Facts

Related News